Success Metrics

Active Trials

2(67%)

Phase Distribution

Ph not_applicable

67%

Ph phase_1

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

N/ANon-phased studies

2(66.7%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Detailed Status

Recruiting2

Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 1

Trials by Phase

Phase 11 (33.3%)

N/A2 (66.7%)

Trials by Status

enrolling_by_invitation133%

recruiting267%

Recent Activity

2 active trials

Showing 3 of 3

recruitingphase_1

R21 Roche: 3-Way Tau Tracers in AD

NCT05464368

enrolling_by_invitationnot_applicable

Molecular PET Imaging and Plasma Biomarkers in Alzheimer´s Disease and Other Neurodegenerative Diseases

NCT06731842

recruitingnot_applicable

Impact of Microglial Activation on Synaptic Density in Alzheimer's Disease

NCT05911178

Clinical Trials (3)

Showing 3 of 3 trials

NCT05464368Phase 1

R21 Roche: 3-Way Tau Tracers in AD

Recruiting

NCT06731842Not Applicable

Molecular PET Imaging and Plasma Biomarkers in Alzheimer´s Disease and Other Neurodegenerative Diseases

Enrolling By Invitation

NCT05911178Not Applicable

Impact of Microglial Activation on Synaptic Density in Alzheimer's Disease

Recruiting

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3